Wolters Kluwer Health announces that following its acquisition of Invistics, its drug diversion monitoring software received recognition from KLAS in the Drug Diversion Monitoring 2023 report. The report highlights the artificial intelligence capabilities, customer satisfaction, ease of use, and effectiveness of the solution in identifying and preventing drug diversion incidents within healthcare organizations. Wolters Kluwer Health provides clinical technology and evidence-based solutions and supports clinical effectiveness, learning and research, clinical surveillance and compliance, and data solutions.